Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Greil

Showing results (271-280 of 483) with videos related to

Pageof 49
Sort By:
Breast (Edinburgh, Scotland)|January 7, 2026
HER2/CEP17 ratio is associated with pCR after HER2-directed neoadjuvant treatment in the phase III NeoALTTO trialChristian F Singer, Franz Koenig, Stephanie Kacerovsky-Strobl, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|January 27, 2011
Preoperative oxaliplatin, capecitabine, and external beam radiotherapy in patients with newly diagnosed, primary operable, cT₃NxM0, low rectal cancer: a phase II studyDietmar Ofner, Alexander F Devries, Renate Schaberl-Moser, et al.
Eclinicalmedicine|November 29, 2023
BendaEAM versus BEAM as conditioning regimen for ASCT in patients with relapsed lymphoma (BEB): a multicentre, randomised, phase 2 trialFelix Keil, Antonia M S Müller, Andrea Berghold, et al.
Blood|February 3, 2016
Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trialsBoris Böll, Helen Goergen, Karolin Behringer, et al.
JAMA Oncology|January 23, 2016
DPYD Genotyping to Predict Adverse Events Following Treatment With Fluorouracil-Based Adjuvant Chemotherapy in Patients With Stage III Colon Cancer: A Secondary Analysis of the PETACC-8 Randomized Clinical TrialValérie Boige, Marc Vincent, Philippe Alexandre, et al.
Journal of Clinical Pathology|December 9, 2015
The clinical significance of fibrinogen plasma levels in patients with diffuse large B cell lymphomaKatharina T Troppan, Thomas Melchardt, Kerstin Wenzl, et al.
Pharmacoeconomics|November 19, 2014
Cost-effectiveness analysis of prognostic gene expression signature-based stratification of early breast cancer patientsPatricia R Blank, Martin Filipits, Peter Dubsky, et al.
European Journal of Haematology|February 14, 2015
The significance of pretreatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patientsKatharina T Troppan, Thomas Melchardt, Alexander Deutsch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 2024
Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER TrialAlexios Matikas, Volker Möbus, Richard Greil, et al.
Cancer|December 19, 2019
Efficacy and safety of tailored and dose-dense adjuvant chemotherapy and trastuzumab for resected HER2-positive breast cancer: Results from the phase 3 PANTHER trialAntroula Papakonstantinou, Alexios Matikas, Nils Olof Bengtsson, et al.
Pageof 49

Showing results (271-280 of 483) with videos related to

Sort By:
Pageof 49
Breast (Edinburgh, Scotland)|January 7, 2026
HER2/CEP17 ratio is associated with pCR after HER2-directed neoadjuvant treatment in the phase III NeoALTTO trialChristian F Singer, Franz Koenig, Stephanie Kacerovsky-Strobl, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|January 27, 2011
Preoperative oxaliplatin, capecitabine, and external beam radiotherapy in patients with newly diagnosed, primary operable, cT₃NxM0, low rectal cancer: a phase II studyDietmar Ofner, Alexander F Devries, Renate Schaberl-Moser, et al.
Eclinicalmedicine|November 29, 2023
BendaEAM versus BEAM as conditioning regimen for ASCT in patients with relapsed lymphoma (BEB): a multicentre, randomised, phase 2 trialFelix Keil, Antonia M S Müller, Andrea Berghold, et al.
Blood|February 3, 2016
Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trialsBoris Böll, Helen Goergen, Karolin Behringer, et al.
JAMA Oncology|January 23, 2016
DPYD Genotyping to Predict Adverse Events Following Treatment With Fluorouracil-Based Adjuvant Chemotherapy in Patients With Stage III Colon Cancer: A Secondary Analysis of the PETACC-8 Randomized Clinical TrialValérie Boige, Marc Vincent, Philippe Alexandre, et al.
Journal of Clinical Pathology|December 9, 2015
The clinical significance of fibrinogen plasma levels in patients with diffuse large B cell lymphomaKatharina T Troppan, Thomas Melchardt, Kerstin Wenzl, et al.
Pharmacoeconomics|November 19, 2014
Cost-effectiveness analysis of prognostic gene expression signature-based stratification of early breast cancer patientsPatricia R Blank, Martin Filipits, Peter Dubsky, et al.
European Journal of Haematology|February 14, 2015
The significance of pretreatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patientsKatharina T Troppan, Thomas Melchardt, Alexander Deutsch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 2024
Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER TrialAlexios Matikas, Volker Möbus, Richard Greil, et al.
Cancer|December 19, 2019
Efficacy and safety of tailored and dose-dense adjuvant chemotherapy and trastuzumab for resected HER2-positive breast cancer: Results from the phase 3 PANTHER trialAntroula Papakonstantinou, Alexios Matikas, Nils Olof Bengtsson, et al.
Pageof 49